Tirofiban

Tirofiban
Systematic (IUPAC) name
(S)-2-(butylsulfonamino)-3-(4-[4-(piperidin-4-yl)butoxy]phenyl)propanoic acid
Identifiers
CAS number	144494-65-5
ATC code	B01AC17
PubChem	60947
DrugBank	APRD00304
Chemical data
Formula	C22H36N2O5S
Mol. mass	440.598 g/mol
Pharmacokinetic data
Bioavailability	n/a (IV only)
Protein binding	65%
Metabolism	?
Half life	2 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Exclusively intravenous

Tirofiban (INN, trade name Aggrastat) is an antiplatelet drug. It belongs to a class of anticoagulants named glycoprotein IIb/IIIa inhibitors. Tirofiban is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.^[1][2]

Contents 1 Basic chemical and pharmacological information 2 Indications 3 Contraindications and precautions 3.1 Cautions 3.2 Use in pregnancy 3.3 Pediatric use 3.4 Other precautions and laboratory exams 4 Side effects 5 Interactions 6 Dosage regimen 7 Duration of therapy 8 Summary of trial results 9 References 10 External links

Basic chemical and pharmacological information

Tirofiban is a synthetic, non-peptide inhibitor acting at glycoprotein (GP) IIb/IIIa receptors in human platelets. It therefore constitutes an anticoagulant, specifically an inhibitor of platelet aggregation.

The drug is marketed under the brand name AGGRASTAT in the US by Medicure Pharma and the rest of the world by Iroko Pharmaceuticals.

It is sold in parenteral dosage forms intended and readily constituted for IV administration containing 5 mg or 12.5 mg, respectively.

Tirofiban has a rapid onset and short duration of action after proper IV administration. Coagulation parameters turn to normal 4 to 8 hours after the drug is withdrawn.

It is a modified version of an anticoagulant found in the venom of the saw-scaled viper Echis carinatus.^[3]

Indications

Tirofiban in combination with heparin and aspirin is indicated in the management of patients with unstable angina or non-Q-wave myocardial infarction, including patients who may subsequently undergo percutaneous transluminal coronary angioplasty (PTCA), to decrease the rate of refractory ischemic conditions, new myocardial infarction and death.

Contraindications and precautions

Tirofiban is contraindicated in patients with:

• known hypersensitivity to any component of the product
• active (internal) bleeding or a history of abnormal bleeding tendencies
• a history of intracranial hemorrhage or neoplasm, arteriovenous malformation, or aneurysm
• patients who developed thrombocytopenia following prior exposure to tirofiban
• known coagulopathy, platelet disorder or history of thrombocytopenia
• stroke within 30 days prior to hospitalization or any history of hemorrhagic stroke
• major surgical procedure or severe physical trauma within the previous month
• history, symptoms or findings suggestive of aortic dissection
• severe uncontrolled hypertension
• acute pericarditis
• cirrhosis or other clinically significant liver disease
• angina caused by obvious provoking factors (arrhythmia, severe anemia, hyperthyroidism or hypotension)

Cautions

Tirofiban should be used with caution in the following clinical situations:

• recent (<1 year) bleeding, including a history of gastrointestinal bleeding, or genitouritary bleeding of clinical significance (e.g. macrohematuria)
• platelet count < 150,000/µl
• history of cerebrovascular disease in the past year
• hemorrhagic retinopathy
• chronic hemodialysis

Use in pregnancy

Tirofiban has been demonstrated to cross the placenta in pregnant rats and rabbits. Although the doses employeed in these studies were a multiple of those used in human beings no adverse effects on the offspring in both animals have been seen. However, there are no adequate and well controlled studies in pregnant women. Therefore, tirofiban should be used during pregnancy only if clearly indicated.

Nursing mothers: It is not known whether tirofiban is excreted in human milk. However, significant levels of tirofiban are excreted in rat milk. Therefore, nursing should be discontinued during the period of drug administration and the milk discarded. Nursing may resume 24 hours after cessation of treatment with tirofiban.

Pediatric use

Safety and effectiveness in children have not been established.

Other precautions and laboratory exams

The activated partial thromboplastin time (aPTT) is the most reliable coagulation parameter and should be obtained regularly during treatment, particular if a bleeding episode occurs that may be assiociated to tirofiban therapy. Other important hematological parameters are platelet count, clotting time, hematocrit and hemoglobin. Proper technique regarding artery site access for sheath placement and removal of sheath should be followed. Arterial sheaths should be removed when the patient's activated clotting time is < 180 sec. or 2 to 6 hours following withdrawal of heparin.

Side effects

The following side effects were noted under treatment with tirofiban and heparin (and aspirin, if tolerated). Other drugs were used as necessary.

The major adverse effect is bleeding on local sites of clinical intervention and systemically (regarding parts of the body or the whole body system). Major bleeding has occurred in 1.4 % of patients and minor bleeding in 10.5 %. Transfusions were required to terminate bleeding and to improve bleeding-related anemia in 4.0 % of all patients. Geriatric patients have experienced more bleeding episodes than younger, women more than man.

Thrombocytopenia was more often seen in the tirofiban + heparin group (1.5 %) than in the heparin control group (0.8 %). This adverse effect was usually readily reversible within days.

Positive fecal and urine hemoglobin tests have also been reported.

Post-marketing events have been the occurrence of intracranial bleeding, retroperitoneal bleeding, pulmonary hemorrhage and spinal-epidural hematoma. Fatal bleedings have been reported rarely.

Sometimes, thrombocytopenia was associated with chills, low-grade fever or bleeding complications (see above).

Cases of hypersenitivity including acute anaphylaxis have been seen.

Interactions

The concomitant application of warfarin or other oral anticoagulants may increase the risk of serious bleeding events. The decision whether maintenance therapy with these drugs should be discontinued during tirofiban treatment has to be made by the responsible clinician.

Dosage regimen

Tirofiban is initially given as rapid intravenous infusion at a rate of 0.4 µg/kg and minute for 30 minutes. Upon completion of the initial infusion, the rate is decreased to 0.1 µg/kg and minute delivered as continuous infusion.

Duration of therapy

Patients who do not show any signs of recurrent ischemic symptoms and do not undergo angiography and angioplasty should be treated for at least 48 hours.

Patients proceeding into angiography and angioplasty should continue throughout both procedures and for at least 12 hours, and not more than 24 hours after angioplasty. Once a patient is clinically stable and no further coronary intervention is planned by the treating physician, the infusion should be discontinued.

Summary of trial results

In the multicenter, randomized, parallel, double-blind PRISM-PLUS trial component endpoints and a composite endpoint were defined for periods of 7 days, 30 days, and 6 months, respectively.

For the 7 days period the following results were obtained:

• Myocardial infarction and death: Risk reduction for tirofiban/heparin compared with heparin alone: 42.8 %.

• Myocardial infarction: Risk reduction for tirofiban/heparin compared with heparin alone: 46.6 %.

• Death : No significant difference.

• Refractory ischemia: Risk reduction for tirofiban/heparin compared with heparin alone: 29.6 %.

• Composite endpoint: Risk reduction for tirofiban/heparin compared with heparin alone: 31.6 %.

All results for the 7 days period were statistically highly significant. At 30 days and 6 months the benefits of tirofiban/heparin remained statistically significant, although the differences to the control group were shrinking.

References

External links

• Tirofiban - Stanford University.
• Aggrastat - Food and Drug Administration (FDA) information.
• Product monograph for Aggrastat - Merck Frosst Canada.

v • d • e Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01) Antiplatelet drugs Glycoprotein IIb/IIIa inhibitors Abciximab • Eptifibatide • Tirofiban ADP receptor/P2Y12 inhibitors (Thienopyridines) Clopidogrel • Ticlopidine • Prasugrel Prostaglandin analogue (PGI2) Beraprost • Prostacyclin • Iloprost • Treprostinil COX inhibitors Acetylsalicylic acid/Aspirin # • Aloxiprin • Carbasalate calcium Other Ditazole • Cloricromen • Dipyridamole • Indobufen • Picotamide • Triflusal Anticoagulants Vitamin K antagonists (inhibit II, VII, IX, X) coumarins: Acenocoumarol • Coumatetralyl • Dicoumarol (Dicumarol) • Ethyl biscoumacetate • Phenprocoumon • Warfarin 1,3-Indandiones: Clorindione • Diphenadione • Phenindione other: Tioclomarol Factor Xa inhibitors (with some II inhibition) Heparin group/ glycosaminoglycans/ (bind antithrombin) low molecular weight heparin (Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Tinzaparin) oligosaccharides (Fondaparinux, Idraparinux) heparinoid (Danaparoid, Sulodexide, Dermatan sulfate) Direct Xa inhibitors xabans (Apixaban, Otamixaban, Rivaroxaban) Direct thrombin (II) inhibitors bivalent: Hirudin (Bivalirudin, Lepirudin, Desirudin) univalent: Argatroban • Dabigatran • Melagatran • Ximelagatran Other Defibrotide • Ramatroban • Antithrombin III • Protein C (Drotrecogin alfa) Thrombolytic drugs/ fibrinolytics plasminogen activators: TPA (Alteplase, Reteplase, Tenecteplase) • UPA (Urokinase, Saruplase) • Streptokinase # • Anistreplase • Monteplase other serine endopeptidases: Ancrod • Fibrinolysin Brinase Non-medicinal Citrate • EDTA • Oxalate #WHO-EM. †Undergoing clinical trials, not FDA approved. ‡Withdrawn from market. §Development halted.